LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS.
“Company”) made available on its website a copy of its investor
presentation that includes an update on the Company’s financial
position to reflect its public offering of common stock announced
March 20, 2017 and further background on its Phase 3 study of
LJPC-501. A copy of this presentation is filed herewith as Exhibit
99.1. The fact that this presentation is being made available and
filed herewith should not be deemed an admission as to the
materiality of any information contained in the materials. The
information contained in the presentation is being provided as of
April 11, 2017, and the Company does not undertake any obligation
to update the presentation in the future.
Form 8-K:
|
Exhibit
No.
|
|
Description
|
|
99.1
|
|
La Jolla Pharmaceutical Company Corporate Presentation
|
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Recent Trading Information
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) closed its last trading session down -0.14 at 25.60 with 513,824 shares trading hands.